Invitation to audiocast for Devyser’s Q1 report 2023
On Tuesday May 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2023 report (which will have been published earlier on May 9, at 07.30 CET). The presentation will be held in English.
Dial-in number to the teleconference and a conference ID will be received by registering on the link below:
https://conference.financialhearings.com/teleconference/?id=200740
The presentation will also be webcast and can be accessed from the following web address:
https://ir.financialhearings.com/devyser-diagnostics-q1-2023
Speakers: CEO Fredrik Alpsten och CFO Sabina Berlin
The information was submitted for publication, through the agency of the contact persons below, on May 4, 2023, at 11:00 CET.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: [email protected]
Tel: +46 706 67 3106
Sabina Berlin, CFO
E-mail: [email protected]
Tel: +46 739 519 502
About Devyser
Devyser develops, manufactures, and sells diagnostic solutions and analytical services to clinical laboratories in more than 50 countries. Our tests are used for advanced genetic testing in the areas of hereditary diseases, oncology, and transplantation, to enable tailored cancer treatment, diagnosis of a large number of genetic diseases and for the follow-up of transplant patients. Devyser's products and unique one-tube method simplify genetic testing processes, improve sample throughput, minimize manual steps, and deliver fast results. Our goal is for each patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in Stockholm. We have 8 own sales offices in Europe and the USA where we also have a service laboratory in Atlanta, Georgia. In August 2022, Devyser's quality management system and Devyser Compact were certified according to the IVDR.
Devyser's shares are traded on Nasdaq First North Premium Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.
For more information, visit devyser.com. Follow us on LinkedIn, Twitter, and Facebook.